{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:58:44Z","timestamp":1789153124338,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40265-024-02130-4","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T02:54:49Z","timestamp":1735008889000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Marstacimab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2130_CR1","unstructured":"Pfizer. U.S. FDA approves Pfizer\u2019s HYMPAVZI\u2122 (marstacimab-hncq) for the treatment of adults and adolescents with hemophilia A or B without inhibitors [media release]. 11 Oct 2024. https:\/\/www.pfizer.com\/."},{"key":"2130_CR2","unstructured":"Pfizer Inc. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use. 2024. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=20916. Accessed 18 Oct 2024."},{"key":"2130_CR3","unstructured":"U.S. Food & Drug Administration. FDA approves new treatment for hemophilia A or B [media release]. 11 Oct 2024. https:\/\/www.fda.gov\/."},{"key":"2130_CR4","unstructured":"Centers for Disease Control and Prevention. Hemophilia. 2024. https:\/\/www.cdc.gov\/hemophilia\/. Accessed 14 Oct 2024."},{"issue":"1","key":"2130_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7(1):1\u20138.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2130_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.18379","volume":"200","author":"K Nogami","year":"2023","unstructured":"Nogami K, Shima M. Current and future therapies for haemophilia-beyond factor replacement therapies. Br J Haematol. 2023;200(1):23\u201334.","journal-title":"Br J Haematol"},{"issue":"S3","key":"2130_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/hae.14976","volume":"30","author":"ME Mancuso","year":"2024","unstructured":"Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024;30(S3):39\u201344.","journal-title":"Haemophilia"},{"key":"2130_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/PPA.S139851","volume":"11","author":"CD Thornburg","year":"2017","unstructured":"Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adher. 2017;11:1677\u201386.","journal-title":"Patient Prefer Adher"},{"issue":"6","key":"2130_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HS9.0000000000000911","volume":"7","author":"G Young","year":"2023","unstructured":"Young G. Nonfactor therapies for hemophilia. HemaSphere. 2023;7(6):1\u20134.","journal-title":"HemaSphere."},{"issue":"5","key":"2130_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/hae.13820","volume":"25","author":"S Patel-Hett","year":"2019","unstructured":"Patel-Hett S, Martin EJ, Mohammed BM, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019;25(5):797\u2013806.","journal-title":"Haemophilia"},{"issue":"2","key":"2130_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, Luis Lamas J, Cristobal Morales J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240\u20138.","journal-title":"Br J Haematol"},{"issue":"7","key":"2130_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.xphs.2018.03.010","volume":"107","author":"C Parng","year":"2018","unstructured":"Parng C, Singh P, Pittman DD, et al. Translational pharmacokinetic\/pharmacodynamic characterization and target-mediated drug disposition modeling of an anti\u2013tissue factor pathway inhibitor antibody, PF-06741086. J Pharm Sci. 2018;107(7):1995\u20132004.","journal-title":"J Pharm Sci"},{"key":"2130_CR13","unstructured":"Pfizer Inc. European Commission approves Pfizer's HYMPAVZI\u2122 (marstacimab) for the treatment of adults and adolescents with severe hemophilia A or B without inhibitors [media release]. 20 Nov 2024. https:\/\/www.pfizer.com\/."},{"key":"2130_CR14","unstructured":"World Intellectual Property Organisation (WIPO). Dosage regimen for tfpi antagonists. 2020. https:\/\/patents.google.com\/patent\/WO2020075083A1\/. Accessed 26 Sep 2024."},{"key":"2130_CR15","unstructured":"World Intellectual Property Organisation (WIPO). Stable aqueous anti-tfpi antibody formulation. 2021. https:\/\/patents.google.com\/patent\/WO2021094917A1\/. Accessed 26 Sep 2024."},{"issue":"9","key":"2130_CR16","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/jth.14207","volume":"16","author":"M Cardinal","year":"2018","unstructured":"Cardinal M, Kantaridis C, Zhu T, et al. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers. J Thromb Haemost. 2018;16(9):1722\u201331.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2130_CR17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/hae.14814","volume":"29","author":"X Sun","year":"2023","unstructured":"Sun X, Liu W, Luo B, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia. Haemophilia. 2023;29(4):1155\u20139.","journal-title":"Haemophilia"},{"issue":"2","key":"2130_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.18420","volume":"200","author":"JN Mahlangu","year":"2023","unstructured":"Mahlangu JN, Lamas JL, Morales JC, et al. A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023;200(2):229\u201339.","journal-title":"Br J Haematol"},{"issue":"2","key":"2130_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rth2.12679","volume":"6","author":"DD Pittman","year":"2022","unstructured":"Pittman DD, Rakhe S, Bowley SR, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022;6(2):1\u201310.","journal-title":"Res Pract Thromb Haemost."},{"key":"2130_CR20","unstructured":"Raje S, Plotka A, Huyghe I, Teeter J. Bioequivalence (BE) of marstacimab prefilled pen (PFP) device and prefilled syringe (PFS) device following subcutaneous (SC) administration in healthy adult males [abstract no. PO036]. Haemophilia. 2022;28(S1):41\u20132."},{"key":"2130_CR21","doi-asserted-by":"crossref","unstructured":"Acharya SS, Matino D, Palladino A, et al. Safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 BASIS trial and ongoing long-term extension study [abstract no. 206 + poster]. In: Thrombosis & Hemostasis Societies of North America (THSNA) Summit, April 4\u20136. 2024.","DOI":"10.1182\/blood-2023-181263"},{"issue":"Suppl. 1","key":"2130_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2023-181263","volume":"142","author":"D Matino","year":"2023","unstructured":"Matino D, Acharya S, Palladino A, et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 Basis trial [abstract]. Blood. 2023;142(Suppl. 1):285\u20137.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"2130_CR23","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1182\/blood-2023-174682","volume":"142","author":"S Acharya","year":"2023","unstructured":"Acharya S, Matino D, Mahlangu J, et al. Marstacimab, an anti-tissue factor pathway inhibitor, in participants with hemophilia \u0391 or B, with and without inhibitors: an integrated analysis of safety [abstract]. Blood. 2023;142(Suppl. 1):3980\u20132.","journal-title":"Blood"},{"key":"2130_CR24","unstructured":"Teeter J, Charnigo R, Cossons N, et al. Safety and efficacy of marstacimab for prevention of bleeding episodes in paediatric patients with severe haemophilia A or moderately severe to severe haemophilia B with or without inhibitors [abstract no. PO122]. Haemophilia. 2022;28(S1):88\u20139."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02130-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:24:32Z","timestamp":1738815872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02130-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}